|Day Low/High||59.60 / 62.23|
|52 Wk Low/High||8.00 / 41.97|
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company ("Catabasis"), and Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne...
We are seeing lower lows in the indices as I write.
Sarepta Therapeutics' (SRPT) stock price target was increased at JMP Securities and RBC Capital on Wednesday due to the potential of Exondys, its Duchenne muscular dystrophy drug.
If the market is looking to correct, election worries are a convenient excuse.
Because every stock has a unique personality that requires its own strategy.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 5.
Relief over the Federal Reserve's slow-and-steady rates plans fueled another day of gains on Thursday.
Stocks rise Thursday as relief over a patient Federal Reserve fuels market gains.
It's challenging to put cash to work but I'll keep digging.
Stock futures move higher on Thursday as relief over a patient Federal Reserve fuels market gains for a second day.
Sarepta (SRPT) disclosed a public offering worth up to $225 million after Wednesday's closing bell.
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in...
BioMarin (BMRN) announced today that it would seek further review of a Patent Trial and Appeal Board ruling over Sarepta's (SRPT) Duchenne muscular dystrophy drug.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has...
Shares of drug-maker Sarepta are higher Tuesday on the back of an upgrade from RBC, but Jim Cramer says he's not adding shares to his portfolio.
Analysts say the Duchenne muscular-dystrophy treatment could be a "major game changer" for Sarepta Therapeutics.
Sarepta Therapeutics' (SRPT) Exondys drug for Duchenne muscular dystrophy was approved by the FDA yesterday, prompting Cowen to raise its rating on the stock to 'outperform' today.
Billionaire activist investor Carl Icahn helped pull down Chesapeake Energy by unveiling a substantial selloff.
Here are Tuesday's top research calls, including upgrades for Wells Fargo and Sarepta, and downgrades for HD Supply and JD.com.
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
Cramer sees Anadarko Petroleum profiting and Coach returning to its former glory.
Worried about a bad event? There will be money coming off the sidelines afterward. Be prepared to buy on weakness.
The FDA provided accelerated approval to Sarepta's (SRPT) Duchenne muscular dystrophy drug and several firms consequently raised the stock's rating.
Concerns are starting to pop up that maybe the Fed statement will have a hawkish tone.